Failure-free survival after initial systemic treatment of chronic graft-versus-host disease

Yoshihiro Inamoto, Mary E.D. Flowers, Brenda M. Sandmaier, Sahika Z. Aki, Paul A. Carpenter, Stephanie J. Lee, Barry E. Storer, Paul J. Martin

Research output: Contribution to journalArticlepeer-review

68 Citations (Scopus)


This study was designed to characterize failure-free survival (FFS) as a novel end point for clinical trials of chronic graft-versus-host disease (GVHD). The study cohort included 400 consecutive patients who received initial systemic treatment of chronic GVHD at our center. FFS was defined by the absence of second-line treatment, nonrelapse mortality, and recurrent malignancy during initial treatment. The FFS rate was 68% at 6 months and 54% at 12 months after initial treatment. Multivariate analysis identified 4 risk factors associated with treatment failure: time interval <12 months from transplantation to initial treatment, patient age ≥60 years, severe involvement of the gastrointestinal tract, liver, or lungs, and Karnofsky score <80% at initial treatment. Initial steroid doses and the type of initial treatment were not associated with risk of treatment failure. Lower steroid doses after 12 months of initial treatment were associated with long-term success in withdrawing all systemic treatment. FFS offers a potentially useful basis for interpreting results of initial treatment of chronic GVHD. Incorporation of steroid doses at 12 months would increase clinical benefit associated with the end point. Studies using FFS as the primary end point should measure changes in GVHD-related symptoms, activity, damage, and disability as secondary end points.

Original languageEnglish
Pages (from-to)1363-1371
Number of pages9
Issue number8
Publication statusPublished - 21-08-2014
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Failure-free survival after initial systemic treatment of chronic graft-versus-host disease'. Together they form a unique fingerprint.

Cite this